Velsera

Velsera is a precision medicine technology company founded in 2023 through the merger of Seven Bridges, PierianDx, and UgenTec. It builds AI-enhanced software and provides expert services for genomics and clinical diagnostics, with particular emphasis on bioinformatics, variant interpretation, NGS interpretation and reporting, and multimodal data harmonisation. The combined experience of its predecessor companies spans more than two decades.

Its product portfolio includes the Seven Bridges bioinformatics environment for genomic data analysis, the Clinical Genomics Workspace for clinical analysis and reporting, ARIA, a data harmonization platform for multimodal data, and an IVD-grade Knowledgebase for variant interpretation. The company reports processing over 250,000 NGS samples annually and serving more than 80 active clinical NGS lab customers.

Velsera works with pharmaceutical, life sciences, clinical diagnostics and NGS assay manufacturing organisations, as well as non-profits, across the US, Europe and Asia. Its work spans drug discovery and development and IVD development and regulatory approval, often in partnership with diagnostic and pharmaceutical partners on problems in genomics and clinical diagnostics.